Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today reported financial results for the second quarter ended June 30, 2009. Optimer reported a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2008 of $8.1 million, or $0.29 per share. The increase in net loss was primarily due to higher research and development expenses. Research and development expenses in the second quarter of 2009 were $10.5 million, compared to $6.2 million in the second quarter of 2008. The increase was primarily due to manufacturing scale-up expenses and expenses to prepare regulatory filings related to the Company's fidaxomicin and prulifloxacin programs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

As of June 30, 2009, Optimer held cash, cash equivalents and short-term investments of $51.2 million.

"During the second quarter, we had the first oral presentations of our North American Phase 3 fidaxomicin data at major scientific conferences showing that fidaxomicin is more effective than oral vancomycin when it comes to reducing recurrence of CDI, even in high risk patient populations," said Michael N. Chang, Ph.D., Optimer's President and Chief Executive Officer. "As we head into the second half of this year, we look forward to presenting additional data from this study at ICAAC and IDSA and we are focused on completing our second fidaxomicin Phase 3 trial and preparing regulatory filings for fidaxomicin and prulifloxacin."

Recent Corporate Highlights

  • Clinical inves
    '/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 New interactive ... innovative thought leaders of the medical device industry ... conference and expo, from June 18-20 in ... http://photos.prnewswire.com/prnh/20130517/613829 ) , These ... industry professionals practical presentations and implementable solutions on ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( ... has been known to react more aggressively when hormones change, ... from puberty, other acne causing factors like P.acnes bacteria and ... skin with unsightly acne scars. Adult acne treatment, Probiotic Action ... on how to reduce and prevent acne scarring. , In ...
(Date:5/17/2013)... WA (PRWEB) May 17, 2013 Tooth decay ... graders showing active signs of the disease. The World Health ... and nearly 100% of adults have cavities. What are the ... is showing a strong connection between the oral bacterial ... is this disease so rampant, yet it is also 100% ...
(Date:5/16/2013)... 16, 2013 A new selection ... from Cole-Parmer is designed to meet the dynamic ... , The new Cole-Parmer® MS-3400 Centrifuges ... the lab. They ensure a powerful and complete ... separation. Their standard four-place swinging buckets hold 50-mL ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3Cole-Parmer Offers Enhanced Selection of Centrifuges 2
... Inc. (OTC Bulletin Board: AIDA) today announced that it,has ... 30, 2007. Net,revenues totaled $7,373,770 for the quarter ended ... 2006. Gross profit decreased by 2.66% due to an,increase ... Aida,s,transfusion and injection forms of etimicin sulfate increased markedly.,Gross ...
... DURHAM, N.C., Nov. 15 AlphaMed Press, publisher ... Phinney and Miodrag Stojkovic as,co-editors. Curt I. ... years of,unprecedented growth in areas of the journal,s ... and number of manuscripts,submitted. During his tenure as ...
... PALO ALTO, Calif., Nov. 15 Jazz,Pharmaceuticals, Inc. ... Myers, the,company,s President, will provide a corporate presentation ... in New York, NY on,November 28, 2007 at ... of the presentation may be accessed by visiting ...
Cached Biology Technology:Aida Files 10Q 2Aida Files 10Q 3Aida Files 10Q 4STEM CELLS Journal Names Co-Editors 2
(Date:5/16/2013)... (May 17, 2013) Illustrating a commitment to ... American Gastroenterological Association (AGA) Research Foundation has announced ... Research Fellowship Award recipients. Supported by the National ... (NIDDK), this new award helps underrepresented minority students ... and nutrition research. , "By establishing this new ...
(Date:5/16/2013)... predict the stability of today,s largest ice sheets in Greenland ... years ago, for example when Earth was going through ... a high sea level due to ice sheet collapse at ... that if the world,s largest ice sheets collapsed in the ... modern, progressively warming world. , However, a new groundbreaking ...
(Date:5/16/2013)... The relationship between the heritable risk for ... clear. Schizophrenia is commonly associated with cognitive impairments ... that reduced IQ may be linked to the ... ability may precede the onset of schizophrenia symptoms. ... relatives of people diagnosed with schizophrenia. , In ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2World's biggest ice sheets likely more stable than previously believed 2Genetic risk for schizophrenia is connected to reduced IQ 2
... have successfully trained a critically endangered marsupial the ... toxic cane toads. Their results, including fascinating behavioural video ... Journal of Applied Ecology and could provide ... against invasive species. In their new study ...
... globally and a tremendous burden on the healthcare system. ... other blood vessels before symptoms occur is needed. With ... from Virginia Tech and GE Global Research Center are ... including a newly patented approach to a long-standing challenge ...
... ANN ARBOR, Mich.The percentage of clinicians who meet ... internship, according to a report posted online that ... Archives of General Psychiatry, one of the JAMA/Archives ... receiving a medical education in the United States are ...
Cached Biology News:Endangered quolls taught to turn their noses up at toxic toad 2Endangered quolls taught to turn their noses up at toxic toad 3New patented technology for improving cardiac CTs receives NIH support 2New patented technology for improving cardiac CTs receives NIH support 3New patented technology for improving cardiac CTs receives NIH support 4New patented technology for improving cardiac CTs receives NIH support 5Depression symptoms increase during medical internship 2
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
AK6 Antibody...
LIGHT DIAGNOSTICS Echovirus Blend Reagent, ~50 tests, included in kit #3340 & #3365...
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
Biology Products: